| |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Register now for updates! |
Please enter your email address
so
that we may provide you with
information about new
materials
and upcoming events |
|
|
 |
|
|
|
|
| |
|
|
| |
|
|
|
 |
|
Chairman:
Frank Giles, MD
Faculty:
Thomas Kipps,
MD
S. Vincent Rajkumar, MD
Richard Stone, MD
Ayalew Tefferi, MD
Kapil Bhalla, MD |
|
 |
|
|
|
|
|
| |
|
| |
|
|
|
|
|
|
This activity has been designed to meet
the educational needs of Hematologists,
Oncologists, Nurse Practitioners and
Physician Assistants involved in the
management of hematologic diseases. |
|
|
|
|
The goal of this program is to provide
important clinical data on the
management of hematologic diseases |
|
| |
|
|
|
|
|
|
| After completing this
activity, the participants should be
better able to: |
|
• |
Describe the disease
burden and the impact of co-morbidities
involving each hematologic |
| |
disorder |
|
|
| • |
Discuss the predictors
of response and tailored treatment
strategies utilized to overcome |
| |
the
unique challenges of difficult to treat
patients |
|
|
| • |
Apply recent clinical
data on the management of hematologic
diseases |
|
|
| • |
Compare and contrast
current treatment options |
|
|
| • |
Review emerging
hematologic therapies |
|
| |
|
| |
|
|
 |
|
This activity is supported by:
Celgene Corporation, Eisai
Pharmaceuticals, Ortho Biotech, and Vion Pharmaceuticals. |
|
|
|
